Surrozen (SRZN)
NASDAQ:SRZN
Want to see SRZN full AI Analyst Report?
SRZN Stock Chart & Stats
$31.56
$0.24(1.85%)
At close: 4:00 PM EST
$31.56
$0.24(1.85%)
Day’s Range― - ―
52-Week Range$8.00 - $35.00
Previous CloseN/A
Volume12.23K
Average Volume (3M)25.24K
Market Cap
$269.94M
Enterprise Value$79.63M
Total Cash (Recent Filing)$106.91M
Total Debt (Recent Filing)$6.78M
Price to Earnings (P/E)―
Beta-0.23
Next Earnings
Aug 06, 2026EPS Estimate
-1.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-41.33
Shares Outstanding11,610,371
10 Day Avg. Volume29,706
30 Day Avg. Volume25,240
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)-0.90
Price to Sales (P/S)48.61
P/FCF Ratio-5.56
Enterprise Value/Market Cap0.29
Enterprise Value/Revenue10.63
Enterprise Value/Gross Profit10.72
Enterprise Value/Ebitda-0.23
Forecast
1Y Price Target
$42.50Price Target Upside34.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-3.98
Revenue Forecast (FY)$6.40M
Bulls Say, Bears Say
Bulls Say
Platform Focus On Wnt SignalingSurrozen's concentrated scientific focus on modulating Wnt signaling is a durable strategic asset: the platform targets tissue repair across multiple organs (liver, intestine, eye), enabling potential multi-indication development, licensing, and long-term value creation if clinical validation proceeds.
Recent Revenue Rebound & Positive Gross ProfitA TTM revenue rebound to roughly $7.5M with recent positive gross profit indicates the company can generate program or collaboration income and cover direct costs on a per-program basis. This suggests underlying program economics may be viable even if overall profitability remains out of reach short-term.
Governance Continuity And Shareholder SupportClear shareholder backing—board re-elections, auditor ratification and advisory pay approvals—provides continuity and lowers governance risk. Stable oversight supports multi-year clinical programs and fundraising, reducing execution uncertainty during the lengthy R&D and regulatory process.
Bears Say
Persistent Heavy Cash BurnSustained negative operating and free cash flow in the mid tens of millions annually creates an ongoing financing requirement. Over the next several months this structural cash burn forces reliance on external capital, risks dilution, and may constrain program advancement if funding terms worsen.
Negative Shareholders' EquityNegative shareholders' equity reflects accumulated losses that erode the capital base and reduce financial flexibility. This structural weakness complicates borrowing or partnering negotiations and increases dependence on equity financings, which can be dilutive and impact long-term strategic optionality.
Very Weak Profitability And Volatile RevenueExtremely negative margins and swings in revenue demonstrate the cost base far exceeds recurring income. The volatility undermines predictable funding and planning; absent consistent, growing revenue or decisive clinical milestones, achieving operating breakeven appears unlikely in the near term.
Surrozen News
SRZN FAQ
What was Surrozen’s price range in the past 12 months?
Surrozen lowest stock price was $8.00 and its highest was $35.00 in the past 12 months.
What is Surrozen’s market cap?
Surrozen’s market cap is $269.94M.
When is Surrozen’s upcoming earnings report date?
Surrozen’s upcoming earnings report date is Aug 06, 2026 which is in 47 days.
How were Surrozen’s earnings last quarter?
Surrozen released its earnings results on May 06, 2026. The company reported -$11.65 earnings per share for the quarter, missing the consensus estimate of -$1.092 by -$10.558.
Is Surrozen overvalued?
According to Wall Street analysts Surrozen’s price is currently Undervalued.
Does Surrozen pay dividends?
Surrozen does not currently pay dividends.
What is Surrozen’s EPS estimate?
Surrozen’s EPS estimate is -1.29.
How many shares outstanding does Surrozen have?
Surrozen has 11,610,371 shares outstanding.
What happened to Surrozen’s price movement after its last earnings report?
Surrozen reported an EPS of -$11.65 in its last earnings report, missing expectations of -$1.092. Following the earnings report the stock price went down -9.903%.
Which hedge fund is a major shareholder of Surrozen?
Currently, no hedge funds are holding shares in SRZN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Surrozen Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$42.50 (34.66% Upside)
$42.50 (34.66% Upside)
Hedge Fund Trend
Increased
By 226.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $4.2M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 8.4%
Last 30 Days ▼ 8.4%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.13%
12-Months-Change
Fundamentals
Return on Equity
309.79%
Trailing 12-Months
Asset Growth
5.12%
Trailing 12-Months
Company Description
Surrozen
Surrozen, Inc. is a biotechnology firm dedicated to discovering and advancing pharmaceutical agents that precisely modify the Wnt pathway to facilitate tissue healing and regeneration. The company engineers specialized antibodies intended for use across a broad spectrum of medical conditions impacting organs such as the intestine, liver, eyes (retina, cornea), lungs, kidneys, inner ear (cochlea), skin, pancreas, and central nervous system. Key assets in their development pipeline include SZN-043, a tissue-targeted R-spondin mimetic designed to address severe liver ailments. Another significant candidate is SZN-1326, a distinctive full-length human bi-specific antibody engineered to directly influence Wnt signaling in specific intestinal tissues by engaging with particular Frizzled and LRP receptors found in intestinal crypts. Surrozen, Inc. was established in 2015 and conducts its operations from its base in South San Francisco, California.
SRZN Stock 12 Month Forecast
Average Price Target
$42.50
▲(34.66% Upside)
Technical Analysis
Opus Genetics
―
Ovid Therapeutics
―
Shattuck Labs
―
Spruce Biosciences
―
Biomea Fusion
―
Ownership Overview
45.74% Insiders
2.87% Mutual Funds
6.48% Other Institutional Investors
43.41% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---